Accent Therapeutics | Translating extraordinary science into life-changing therapeutics for patients living with cancer
Summary
Financing led by Mirae Asset Capital Life Science with participation from additional new and existing investorsFunds will support advancement of lead programs through early clinical development, including Accents first-in-class DHX9 inhibitor and newly unveiled, potentially best-in-class KIF18A inhibitorLEXINGTON, Mass., January 23, 2024 Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing. "We are delighted to announce the backing of an exceptional investor syndicate who share our commitment to advancing innovative therapies for patients with cancer," said Shakti Narayan, PhD, JD, CEO of Accent Therapeutics. "Accents focus on targeting cancer cell vulnerabilities in a specific and robust way really stood out as we were evaluating companies for our first investment, " remarked Naveen Krishnan, MD, MPhil, of Mirae Asset Capital Life Science. "They have assembled an incredible team with a successful track record of drug development, and we are excited to partner with the other seasoned investors to support Accent at this pivotal time. Our strategy is rooted in core principles that include delivering near-term value, calculated risk, finding innovative yet validated modalities, and rigorous evaluation using our unique backgrounds across biomedical research, drug discovery, company building, clinical/medical training, and venture capital investing.